Skip to content

Orphans in Kenya respond well to antiretroviral therapy

Urban myth deters men in London from seeking sexual health screens

Bevirimat, first maturation inhibitor: tablet formulation provides lower than expected plasma levels

Gut microbes linked to immune activation, HIV disease progress, may explain long-term CD4 loss

After 48 weeks of study, and 24 weeks in the real world, darunavir continues to show staying power

TB-related immune reaction to HIV therapy occurs 20 months after TB treatment first started - is this a record?

A simpler, cheaper way to assess HIV-positive children’s health

Emergence of resistance mutations: a comparison between drug classes

TB transmission in healthcare settings and improving infection control